dsm-firmenich completes US$10M upgrade at USA premix facility

USA – dsm -firmenich has completed a US$10 million upgrade of its premix facility in Schenectady, New York, positioning the site as a flagship production hub for the Americas and strengthening capabilities across food, dietary supplement and infant nutrition markets.

The modernisation programme, announced on Wednesday, 11 March, aims to enhance quality standards, operational efficiency and sustainability at the site, which the company says is now among the most advanced human-health premix facilities in North America.

According to dsm-firmenich, the investment reflects increasing regulatory scrutiny and growing customer expectations for traceability, reliability and consistent product quality in nutrition and food ingredient supply chains.

The project focused on redesigning production areas and installing advanced processing technologies to improve manufacturing performance and audit readiness.

Key upgrades include optimised GMP zoning, improved material flow systems, expanded material conditioning and powder technologies and a centralised dispensary and 35 blenders.

The company said the new layout and equipment platform will support cleaner, safer and more efficient operations while enabling faster commercialisation of premix blends.

The Schenectady site produces premix solutions used in human nutrition applications, including fortified foods, dietary supplements and infant formula.

With regulatory requirements tightening globally, ingredient suppliers are increasingly investing in facilities that can demonstrate strong compliance and audit performance.

Maximilian Fattinger, vice president of premix at dsm-firmenich, said: “This investment goes well beyond incremental upgrades. By taking a generational step forward in premix excellence, we are raising the bar for quality, safety and reliability so customers can count on consistent performance and dependable supply.”

Originally established in 1995, the Schenectady facility has been redesigned not only to improve production capabilities but also to increase transparency with customers.

The company said the site will host visitors, giving partners insight into manufacturing systems, quality processes and technical expertise behind its premix solutions.

The investment also aligns with the company’s broader focus on operational resilience and supply continuity for customers navigating increasingly complex regulatory and market conditions.

Headquartered in Switzerland and the Netherlands, dsm-firmenich operates in nearly 60 countries. Recently, the company announced the successful expansion of its human milk oligosaccharide (HMO) portfolio in China, Malaysia, and Thailand.

 Its 3’-sialyllactose (3’-SL) sodium salt ingredient has been approved for use in early life nutrition in the markets, alongside the authorization of 2’fucosyllactose/difucosyllactose (2FL/DFL), lacto-N-tetraose (LNT), and 6’-sialyllactose (6’-SL) sodium salt in Malaysia and Thailand.

To receive our email newsletters with the latest news and insights from Africa, the Middle East and around the world, SUBSCRIBE HERE